Exelixis announces results from COMET-1 phase 3 pivotal trial of cabozantinib
Exelixis announced top-line results from the final analysis of COMET-1, the phase 3 pivotal trial of cabozantinib in men with mCRPC whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint. September 01, 2014